Clinical Trials for Mesothelioma Patients: Novartis LBH589 Inclusion Criteria

Read about the inclusion criteria for a current clinical trial being conducted to study the effects of Novartis LBH589 for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. For additional information, contact Novartis at 1-800-340-6843.

Inclusion Criteria

1. Age = 18 years

2. At time of diagnosis or relapse, histologically confirmed NSCLC with locally advanced or metastatic disease (stage IIIA, IIIB, or IV) or histologically confirmed mesothelioma of the pleura which is unresectable

3. Must have failed prior standard systemic therapy

NSCLC patients must have failed at least two prior therapies, including a platinum-based chemotherapy regimen ? Malignant Pleural Mesothelioma patients must have failed at least one pemetrexed- or cisplatin-based chemotherapy regimen

4. Must have measurable disease (by computerized tomography [CT] or magnetic resonance imaging [MRI]) per disease specific criteria (RECIST criteria for NSCLC and modified RECIST criteria for mesothelioma)

5. Mesothelioma patients may have undergone pleurodesis

6. Written informed consent obtained prior to any screening procedures

7. Willingness to have multiple blood draws

8. Ability to swallow capsules or tablets

Courtesy of ClinicalTrials.gov.

Other helpful links:

Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney